Abstract:Objective: Comparative genomic hybridization (CGH) is a new molecular and cellular technology developed from fluorescence in situ hybridization (FISH). It is a molecular cytogenetics method used to examine genomic imbalances, especially the deletion and amplification of chromosomes, and to locate these alterations in certain chromosome regions. To completely understand the possible differences in genomic DNA between three paclitaxel-resistant nasopharyngeal carcinoma cell lines (CNE1/Taxol, HNE2/Taxol, 5-8F/Taxol) and corresponding parent cells (CNE1, HNE2, 5-8F) which were sensitive to paclitaxel medication, and the significance of the differences in nasopharyngeal carcinoma acquired drug-resistance, the genomic DNA of three paclitaxel-resistant nasopharyngeal carcinoma cell lines and their parent cell lines were detected and analyzed using comparative genomic hybridization (CGH). Methods: The three paclitaxel-resistant nasopharyngeal carcinoma cell lines (CNE1/Taxol, HNE2/Taxol, 5-8F/Taxol) were created by combining high-dose pulse therapy in the parent cells with stepwise dose increments of paclitaxel. The resistance index was determined by colony formation. Cell CGH was performed on paclitaxel-resistant nasopharyngeal carcinoma cell lines and the parent cell lines to explore the changes in chromosomal DNA regions. Results: The resistance indices of the three paclitaxel-resistant nasopharyngeal carcinoma cell lines (CNE1/Taxol, HNE2/Taxol, 5-8F/Taxol) were 8.43, 8.27 and 5.26, respectively. There were extensive chromosomal changes in the three parent cell lines when compared to normal genomic DNA, mainly seen in the co-amplification of 3q21-qter, 5p13-pter, 12 and 20q11-qter, and the common deletion of 10q11-qter, 18 and X in all three parent cell lines. However, the three paclitaxel-resistant cell lines showed a relatively normal karyotype with changes mainly in the co-amplification of 3q21-qter, 5p13-pter, 12, 20q11-qter and 8q21-qter. Compared with the common amplifications in parent cell lines, a new co-amplification of 8q21-qter was detected in the three paclitaxel-resistant nasopharyngeal carcinoma cell lines. Conclusion: Co-amplification of 3q21-qter, 5p13-pter, 12 and 20q11-qter, and deletion of 10q11-qter, 18, and X may be associated with nasopharyngeal carcinoma. Chromosomal amplification of 8q21-qter may be related to paclitaxel-resistance in nasopharyngeal carcinoma cell lines. Further studies on these chromosome regions may supply new clues on the occurrence of nasopharyngeal carcinoma and the mechanism of acquired resistance of nasopharyngeal carcinoma to paclitaxel.

[Synergistic interactions of TRAIL and paclitaxel on the nasopharyngeal carcinoma cell lines in vitro].

[Synergistic interactions of TRAIL and paclitaxel on the laryngeal squamous carcinoma cell line in vitro].

[Synergistic Effects and Mechanisms of Combined Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Chemotherapeutic Drugs or Radiotherapy in Killing Laryngeal Squamous Carcinoma Cells in Vitro].

Effects of TRAIL combined with cisplatin on Hep-2 laryngeal squamous carcinoma in vitro

The Apoptotic Pathway of Laryngeal Squamous Carcinoma Cell Line Induced by Combined TRAIL with Chemotherapeutic Drugs or Radiotherapy

A Clinical Research of Paclitaxel or Docetaxel Combined with Cisplatin in Treating Advanced Nasopharyneal Carcinoma

Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma

Timosaponin AIII Suppresses RAP1 Signaling Pathway to Enhance the Inhibitory Effect of Paclitaxel on Nasopharyngeal Carcinoma

Paclitaxel Sensitizes Gastric Cancer Cells to TRAIL-induced Apoptosis

[Combination of Cytosine Arabinoside and Cisplatin Enhances Inhibition of Cell Proliferation and Promotes Apoptosis of Resistant Nasopharyngeal Carcinoma Cells].

Paclitaxel Enhances Tumoricidal Potential of TRAIL Via Inhibition of MAPK in Resistant Gastric Cancer Cells.

The efficiency of liposomal paclitaxel versus docetaxel in neoadjuvant chemotherapy with the TPF regimen for locally advanced nasopharyngeal carcinoma: a retrospective study

Apoptosis and Survivin mRNA expression of undifferential NPC cell line CNE-2 induced by Paclitaxel

Studies on Comparative Genomic Hybridization between Multiple Types of Paclitaxel-resistant Nasopharyngeal Carcinoma Cells and the Parent Cell Lines

Synergistic Anticancer Effects Achieved by Co-Delivery of TRAIL and Paclitaxel Using Cationic Polymeric Micelles

Metadherin-mediated Cell Proliferation and Paclitaxel Resistance in Nasopharyngeal Carcinoma

Use of Taxane-Containing Induction Chemotherapy in Combination with Concurrent Chemoradiotherapy in Chinese Patients with Locally Advanced Nasopharyngeal Carcinoma: a Meta-Analysis

Apoptosis Induced By Low-Dose Paclitaxel Is Associated With P53 Upregulation In Nasopharyngeal Carcinoma Cells

Clinical observation of paclitaxel liposome combined with cisplatin in advanced nasopharyngeal carcinoma

Establishment of a paclitaxel-resistant human nasopharyngeal carcinoma cell line and study of its mechanisms

[Expression and Significance of Survivin Mrna in Xenotransplanted Nasopharyngeal Carcinoma Treated by Paclitaxel Combined with Radiotherapy].